the impact of novel anticancer therapies on blood pressure and kidney function in patients with ckd
Published 1 month ago • 314 plays • Length 1:00:11Download video MP4
Download video MP3
Similar videos
-
8:18
pearls of acs diagnosis: the heart score
-
3:26
fondazione ri.med 360 animation v2
-
2:43
resistance mechanisms of current treatments in cll
-
17:45
professor geoffrey lindeman - brca-p & breast cancer prevention - research, risks & recovery q&a
-
0:55
the impact of mrd & genetics on outcomes to time-limited combinations in patients with cll
-
3:10
tailoring cll therapy
-
5:37
pemeriksaan hba1c
-
21:15
dose prescription in crrt - s. goldstein
-
10:30
preventative double mastectomy & reconstruction results update! what i regret from recovery ❤️
-
2:18
jan lindmeyer // be you. be bayer.
-
3:17:51
webinar for clinicians - brca genetic testing and risk management
-
47:34
dcb academy - complete vs non-complete revascularization in current era interventional cardiology
-
1:00
bruin cll-322 update: fixed-duration pirtobrutinib plus vr vs vr in patients with r/r cll
-
0:14
clr 06 b3
-
1:33
dr. johanna jenkins, orthodontist
-
7:18
cll genetic tests: how do results impact treatment and care?
-
1:26
preclinical safety and efficacy of cd123-nk cell engager in r/r aml
-
0:23
you've been heard. #5
-
35:46
cll patient expert q&a: dr. danielle brander
-
2:07
efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
-
4:22
summary: reduce risk of patient harm